CHF 6297

Drug Profile

CHF 6297

Alternative Names: CHF6297

Latest Information Update: 07 Jul 2016

Price : $50

At a glance

  • Originator Chiesi Farmaceutici
  • Class Corticosteroids
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Jan 2016 Phase-I/II clinical trials in Chronic obstructive pulmonary disease in United Kingdom (unspecified route) (NCT02815488)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top